KORU Medical Systems Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

STOCK-BASED COMPENSATION (Details Narrative)

STOCK-BASED COMPENSATION (Details Narrative) - USD ($)						3 Months Ended	12 Months Ended
STOCK-BASED COMPENSATION (Details Narrative) - USD ($)	Jan. 02, 2021	May 20, 2019	Apr. 23, 2019	Apr. 02, 2019	Feb. 02, 2019	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Independent Directors [Member]
Description of payment terms	Each non-employee director of the Company (other than the Chairman of the Board) and Board advisor are eligible to receive of $75,000 annually, to be paid quarterly $12,500 in cash and $6,250 in common stock. In addition, for chairing the Audit Committee, Compensation Committee and the Nominating and Corporate Governance Committee, each non-employee director is eligible to receive annually $15,000, $11,500 and $7,500 respectively, to be paid quarterly in cash and subject to proration for partial quarter service. The Chairman of the Board is eligible to receive $100,000 annually, to be paid quarterly $12,500 in cash and $12,500 in common stock.
Non-Employee Director [Member]
Description of payment terms	Each non-employee director of the Company was eligible to receive $50,000 annually (effective January 1, 2019), plus $10,000 for chairing a Board committee (effective February 20, 2019), all to be paid quarterly half in cash and half in common stock. The Chairman of the Board was eligible to receive an additional $50,000 annually (effective October 1, 2019), all to be paid in common stock. All payments were pro-rated for partial service. The Company issued an aggregate 32,181 shares of common stock to its non-employee directors during the year ended December 31, 2020, respectively.
Employment Agreement [Member] \| Chief Executive Officer, Mr. Goldberger [Member]
Number of shares authorized to employees					90,604
Description of payment terms				A performance bonus in the amount of $270,000 to be paid half in cash and half in stock.
EMED Technologies Corporation [Member] \| Settlement Agreement [Member]
Description of vesting rights		The Company issued to EMED (i) 95,238 restricted stock units, which vested on May 21, 2020 and 95,238 restricted stock units vesting on January 1, 2021, and (ii) an option to purchase up to 400,000 shares of the Company’s common stock at an exercise price of $11.21 per share prior to February 1, 2021, which can be settled in cash in lieu of common stock at the Company’s sole discretion, provided that the number of shares of common stock and/or amount of cash paid by the Company upon exercise will be capped at a value of $16.21 per share. The option was recorded at $347,008, the estimated fair value of the option using the Black-Scholes option pricing model with a volatility rate of 52.68% and a risk-free rate of 0.17%.
Non-cash expense						$ 2,200,000
2015 Stock Option Plan [Member]
Number of shares authorized to employees			6,000,000
2015 Stock Option Plan [Member] \| Time Based Shares Options [Member]
Weighted average grant date fair value of stock options							$ 6.53	$ 1.33
Allocated stock-based compensation expense							$ 874,869	$ 594,956
Weighted-average grant-date fair value options granted							2,350,264	2,202,678
Total unrecognized compensation cost							$ 3,376,990
Weighted-average period (in years)							48 months
Total fair value of shares vested							$ 803,171	539,553
Cash received from option exercises							$ 95,880	$ 58,900
Number of options exercised							397,962	58,900
2015 Stock Option Plan [Member] \| Performance Based Share Options [Member]
Weighted average grant date fair value of stock options								$ 1.16
Allocated stock-based compensation expense							$ 502,904	$ 293,363
Weighted-average grant-date fair value options granted							0	1,162,561
Total unrecognized compensation cost							$ 366,294
Weighted-average period (in years)							25 months
Total fair value of shares vested							$ 387,520	$ 0